Oral administration of recombinant Mycobacterium smegmatis expressing a tripeptide construct derived from endogenous and microbial antigens prevents atherosclerosis in ApoE −/− mice

ConclusionsOur results suggest that M. smegmatis can be developed as an oral carrier of recombinant proteins to treat inflammatory autoimmune diseases.

Source: Cardiovascular Therapeutics - September 27, 2016 Category: Cardiology Authors: Vrushali Deshpande, Rameshkumar Krishnan, Sheena Philip, Ildiko Faludi, Thiruvelselvan Ponnusamy, Lakshmi Narasimha Rao Thota, Valeria Endresz, Xinjie Lu, Vijay V. Kakkar, Lakshmi A. Mundkur Tags: Original Research Article Source Type: research